Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | MC3R | P41968 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.32 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.32 |
| ▸ | F7 | P08709 | 1/20 | 0.32 |
| ▸ | F3 | P13726 | 1/20 | 0.32 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.32 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.32 |
| ▸ | NNMT | P40261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL352483 | 0.80 | SPR (0.45) | SPRTSHRADORA3MC4RADRA1A | |
| SCHEMBL28170830 | 0.78 | NNMT (0.41) | TSHRADORA3MC4RADRA1AMC3R | |
| Hydrochloric Acid SCHEMBL15900077 | 0.77 | SPR (0.36) | SPR | |
| SCHEMBL23925748 | 0.77 | ADORA3 (0.36) | SPRTSHRADORA3MC4RADRA1A | |
| SCHEMBL30338528 | 0.77 | ADORA3 (0.36) | TSHRADORA3MC4RADRA1AMC3R | |
| SCHEMBL15006471 | 0.77 | SIRT3 (0.41) | TSHRADORA3MC4RADRA1AMC3R | |
| SCHEMBL13771965 | 0.74 | GABRP (0.36) | TSHRADORA3MC4RADRA1AMC3R | |
| SCHEMBL20171265 | 0.74 | CYP11B2 (0.43) | MKNK1MKNK2CHUK | |
| SCHEMBL13765814 | 0.72 | LMNA (0.39) | TSHRADORA3MC4RADRA1AMC3R | |
| SCHEMBL27984896 | 0.72 | AR (0.45) | TSHRADORA3MC4RADRA1AMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210008069-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-01-14 | — | — | US | disclosed |
| EP-3756671-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE | Daiichi Sankyo Company, Limited (JP) | 2020-12-30 | — | — | EP | disclosed |
| CN-112074272-A | Therapeutic agent for inflammatory bowel disease | 第一三共株式会社 | 2020-12-11 | — | — | CN | disclosed |
| US-20190151315-A1 | Drug For Preventing Or Treating Lactic Acidosis | KEIO UNIVERSITY (JP) | 2019-05-23 | — | — | US | disclosed |
| EP-3441070-A1 | DRUG FOR PREVENTING OR TREATING LACTIC ACIDOSIS | Keio University (JP) | 2019-02-13 | — | — | EP | disclosed |
| US-20190000847-A1 | THERAPEUTIC AGENT FOR A WOUND | DAIICHI SANKYO COMPANY LIMITED (JP) | 2019-01-03 | — | — | US | disclosed |
| CN-108883113-A | The medicine of prevention or the treatment of lactic acidosis | 学校法人庆应义塾 | 2018-11-23 | — | — | CN | disclosed |
| EP-3391887-A1 | WOUND TREATMENT AGENT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-10-24 | — | — | EP | disclosed |
| CN-108367007-A | Therapeutic agent for wound | 第三共株式会社 | 2018-08-03 | — | — | CN | disclosed |
| EP-2832726-B1 | (2-HETEROARYLAMINO)SUCCINIC ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-20050171038-A1 | N-allyl-3-{2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide with HIV enzyme inhibitor | AGOURON PHARMACEUTICALS, INC. | 2005-08-04 | — | — | US | disclosed |
| US-20050171037-A1 | Therapeutic combinations | AGOURON PHARMACEUTICALS, INC. | 2005-08-04 | — | — | US | disclosed |
| US-20050165040-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | disclosed |
| WO-2005056542-A1 | COMPOSITIONS COMPRISING AN HIV PROTEASE INHIBITOR | PFIZER INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20050129772-A1 | Compositions comprising an HIV protease inhibitor | AGOURON PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | disclosed |
| US-20050124683-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2005026114-A1 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME AND THEIR PHARMACEUTICAL USES | PFIZER INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20040204591-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2004-10-14 | — | — | US | disclosed |
| US-20040171842-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis | PFIZER INC | 2004-09-02 | — | — | US | disclosed |
| WO-2004067531-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050129772-A1 | Compositions comprising an HIV protease inhibitor | DPP4, DNPEP, DPP3 | SPR 96/4885TSHR 4879/4885ADORA3 3126/4885 |
| US-20050171038-A1 | N-allyl-3-{2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide with HIV enzyme inhibitor | DNPEP, ANPEP, AADAC | SPR 138/4885TSHR 4748/4885ADORA3 589/4885 |
| US-20210008069-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE | SLC10A2, FABP2, SI | SPR 2162/4885TSHR 4661/4885ADORA3 619/4885 |
| US-20190151315-A1 | Drug For Preventing Or Treating Lactic Acidosis | LDHA, LDHB, SLC16A1 | SPR 3031/4885TSHR 2615/4885ADORA3 290/4885 |
| US-20040171842-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis | SERPINB1, PEPD, PREP | SPR 181/4885TSHR 4867/4885ADORA3 4438/4885 |
| US-20050171037-A1 | Therapeutic combinations | CYP3A43, TMPRSS15, CYP3A5 | SPR 42/4885TSHR 4454/4885ADORA3 2020/4885 |
| US-20050124683-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | PEPD, SERPINB1, ACE | SPR 263/4885TSHR 4876/4885ADORA3 3395/4885 |
| US-20050165040-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | POLB, APOBEC3C, IDH3A | SPR 550/4885TSHR 4826/4885ADORA3 2833/4885 |
| US-20190000847-A1 | THERAPEUTIC AGENT FOR A WOUND | MMP8, CCL11, C3AR1 | SPR 2636/4885TSHR 4585/4885ADORA3 1887/4885 |
| US-20040204591-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | FURIN, PREP, PRSS1 | SPR 97/4885TSHR 4878/4885ADORA3 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.